The United States Food and Drug Administration (USFDA) has determined the inspection classification status of Unit II, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, situated at Bhiwadi, Alwar, Rajasthan, as ‘Official Action Indicated (OAI)’.
The USFDA had conducted an inspection from April 25 to May 3, 2024 at this facility. The company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
